Paris has cemented its position as a European powerhouse for turning laboratory discoveries into patented innovations, with three French research institutes now dominating the continent’s patent filings.
The European Patent Office (EPO) released its first comprehensive analysis of more than 800 technology transfer offices across 46 countries. The report arrives as Europe races to convert its scientific excellence into commercial technologies and competitive businesses. Technology transfer offices play a central role in that pipeline, helping researchers protect inventions and connect with companies and investors.
Public research institutions now account for 34% of European patent applications in biotechnology, 29% in quantum technologies, and 26% in pharmaceuticals. University-linked patents represent about 9% of all European filings, a level that rivals the United States. Meanwhile, annual patent applications involving universities, public research organizations, or research hospitals have jumped from roughly 3,200 in 2006 to nearly 8,000 in 2025.
French institutions stand at the forefront. The CNRS ranks as Europe’s leading public research organization by patent volume, filing 729 applications with particular strength in pharmaceuticals, biotechnology, and measurement technologies. The CEA, focused on atomic and alternative energy, placed third with 528 applications and emerged as a key player in semiconductors and low-carbon energy. INSERM, the national health and medical research institute, secured fourth place with 432 applications.
Two French universities also performed strongly. Université Paris Cité ranked ninth and Sorbonne Université placed eleventh, both cited for what the EPO calls strong interdisciplinary innovation momentum.
France’s research-to-business pipeline extends beyond patents. The EPO’s Deep Tech Finder identifies 633 French spin-offs or startups originating from research, second in Europe behind the United Kingdom. French Technology Transfer Acceleration Companies, known as SATTs, have helped create nearly 1,000 startups by bridging the gap between public laboratories and commercial ventures. As a result, France now ranks among Europe’s most effective systems for converting scientific breakthroughs into market-ready enterprises.
